Abstract
PUMA (p53 upregulated modulator of apoptosis) is a Bcl-2 homology 3 (BH3)-only Bcl-2 family member and a key mediator of apoptosis induced by a wide variety of stimuli. PUMA is particularly important in initiating radiation induced apoptosis and damage in the gastrointestinal and hematopoietic systems. Unlike most BH3-only proteins, PUMA neutralizes all five known antiapoptotic Bcl-2 members through high affinity interactions with its BH3 domain to initiate mitochondria-dependent cell death. Using structural data on the conserved interactions of PUMA with Bcl-2-like proteins, we developed a pharmacophore model that mimics these interactions. In silico screening of the ZINC 8.0 database with this pharmacophore model yielded 142 compounds that could potentially disrupt these interactions. Thirteen structurally diverse compounds with favorable in silico ADME/Toxicity profiles have been retrieved from this set. Extensive testing of these compounds using cell-based and cell-free systems identified lead compounds that confer considerable protection against PUMA-dependent and radiation-induced apoptosis, and inhibit the interaction between PUMA and Bcl-xL.
Keywords: Inhibition of PUMA-induced apoptosis, Bcl-2 protein family, BH3 domain, protein-protein interactions, pharmacophore modeling, druggability, virtual screening of libraries of small compounds, PUMA Inhibitors, p53 upregulated modulator of apoptosis, Bcl-2 homology, hematopoietic systems, programmed cell death, neurodegenerative diseases, autoimmune disorders, radiotherapy, DNA damage, caspases, mitochondrial apoptotic pathway, cytochrome c, mitochondrial dysfunction, ZINC 8.0 database, ADME/Tox, molecular dynamics, colon cancer cells, adenovirus, DLD1 cells, Adriamycin, cyclin-dependent kinase, p21 KO cells, immunoprecipitation, inflammatory cytokines, reactive oxygen species, chemotherapy, anticancer therapies, CYP2D6 inhibition, Cell Culture, Molecular Probes, Western Blotting
Current Topics in Medicinal Chemistry
Title: Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death
Volume: 11 Issue: 3
Author(s): Gabriela Mustata, Mei Li, Nicki Zevola, Ahmet Bakan, Lin Zhang, Michael Epperly, Joel S. Greenberger, Jian Yu and Ivet Bahar
Affiliation:
Keywords: Inhibition of PUMA-induced apoptosis, Bcl-2 protein family, BH3 domain, protein-protein interactions, pharmacophore modeling, druggability, virtual screening of libraries of small compounds, PUMA Inhibitors, p53 upregulated modulator of apoptosis, Bcl-2 homology, hematopoietic systems, programmed cell death, neurodegenerative diseases, autoimmune disorders, radiotherapy, DNA damage, caspases, mitochondrial apoptotic pathway, cytochrome c, mitochondrial dysfunction, ZINC 8.0 database, ADME/Tox, molecular dynamics, colon cancer cells, adenovirus, DLD1 cells, Adriamycin, cyclin-dependent kinase, p21 KO cells, immunoprecipitation, inflammatory cytokines, reactive oxygen species, chemotherapy, anticancer therapies, CYP2D6 inhibition, Cell Culture, Molecular Probes, Western Blotting
Abstract: PUMA (p53 upregulated modulator of apoptosis) is a Bcl-2 homology 3 (BH3)-only Bcl-2 family member and a key mediator of apoptosis induced by a wide variety of stimuli. PUMA is particularly important in initiating radiation induced apoptosis and damage in the gastrointestinal and hematopoietic systems. Unlike most BH3-only proteins, PUMA neutralizes all five known antiapoptotic Bcl-2 members through high affinity interactions with its BH3 domain to initiate mitochondria-dependent cell death. Using structural data on the conserved interactions of PUMA with Bcl-2-like proteins, we developed a pharmacophore model that mimics these interactions. In silico screening of the ZINC 8.0 database with this pharmacophore model yielded 142 compounds that could potentially disrupt these interactions. Thirteen structurally diverse compounds with favorable in silico ADME/Toxicity profiles have been retrieved from this set. Extensive testing of these compounds using cell-based and cell-free systems identified lead compounds that confer considerable protection against PUMA-dependent and radiation-induced apoptosis, and inhibit the interaction between PUMA and Bcl-xL.
Export Options
About this article
Cite this article as:
Mustata Gabriela, Li Mei, Zevola Nicki, Bakan Ahmet, Zhang Lin, Epperly Michael, S. Greenberger Joel, Yu Jian and Bahar Ivet, Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death, Current Topics in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/156802611794072641
DOI https://dx.doi.org/10.2174/156802611794072641 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stereotactic Body Radiation Therapy in Head and Neck Squamous Cell Carcinoma: Science or Art?
Current Cancer Therapy Reviews Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Research Progress of Axl Inhibitors
Current Topics in Medicinal Chemistry Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Parathyroid Hormone Determination in Ultrasound-Guided Fine Needle Aspirates Allows the Differentiation between Thyroid and Parathyroid Lesions: Our Experience and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Applications of Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics
Combinatorial Chemistry & High Throughput Screening Preface
Clinical Cancer Drugs Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued)